HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

UCB inks $2B Candid buyout to join Gilead in autoimmune field

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-cell engagers.

By FierceBiotech · May 5, 2026 · via FierceBiotech
UCB inks $2B Candid buyout to join Gilead in autoimmune field

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
UCB bets $2B on Candid's T cell engager ambitions
DealsEndpoints News ↗
UCB bets $2B on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
May 4, 2026
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026